Please enjoy this week’s flags for recently filed IPO prospectuses. Remember, this Substack is only meant to provide quick text summaries, with a deeper 3-page overview if you’d like to know more.

None of our content is meant to be taken as investment advice or validity of the proposed company/IPO.

Enjoy.

This Week’s IPOs

LIS Technologies

LIS Technologies (proposed LIS / Nasdaq Capital Market) filed its S-1 on October 26, 2026, offering 2,833,334 primary shares at an indicative $5-$7. At the filing’s $6 midpoint, estimated net proceeds are approximately $15.1 million; final pricing remains undisclosed. Planned uses are 67.5% for technology and site development, 12.5% for marketing/business development and 20% for working capital and general purposes.

The Oak Ridge company develops laser-based uranium enrichment using its CRISLA process. Proprietary process knowledge and potential domestic enrichment demand support its development rationale, but commercial-scale performance and cost advantages are unproven. Its security procedures plan remains contingent on an NRC readiness review and is not a commercial enrichment license. Pilot and commercial-facility timelines are management targets.

For the nine months ended July 31, 2026, LIS reported no operating revenue, a $29.688 million net loss, $14.819 million operating cash outflow and $24.876 million cash capex. Period-end cash was $18.792 million. Management concludes discretionary-spending deferrals alleviate initial going-concern doubt, while the full development program requires additional financing. Regulatory execution, construction, technology and award dilution remain material risks.

What to monitor: final offer terms, regulatory readiness and licensing, technical validation, spending commitments and financing beyond this offering.

Source: October 26 S-1; CIK 1973276; accession 0001493152-26-048438.

Lis Ipo 2026 10 30

105KB ∙ PDF file

Download

Download

KAT Construction Services

KAT Construction Services (proposed KATX / NYSE American and NYSE Texas) filed its S-1 on October 29, 2026. It proposes 3,333,334 primary shares at $5-$7; final pricing is undisclosed. At the $6 midpoint, estimated net proceeds are $17.750 million, with $10 million allocated to unidentified acquisitions and the remainder to working capital, marketing, facility repayment and capex.

KAT fabricates and installs countertops and stone surfaces, primarily in Dallas-Fort Worth. Customer relationships, local execution and commercial, multifamily and residential operations support its business position, while regional concentration, skilled labor and Home Depot dependence constrain diversification. Historical results belong to the operating LLC before its August 2026 corporate conversion.

First-half 2026 revenue fell 35.6% to $6.414 million; gross margin declined to 33.0%. Net loss was $85,873, operating cash inflow $153,537 and cash capex $68,634. June 30 cash was $571,694 against $2.488 million debt carrying value, excluding leases.

Convertible preferred carries 100 votes per share and concentrated control. The filing contains inconsistent voting, share-count and repayment disclosures, which the report separates and recalculates. Conditional adviser equity prevents a fixed fully diluted share count.

What to monitor: final pricing, corrected transaction disclosures, acquisition commitments, revenue stabilization and financing costs.

Source: October 29 S-1; CIK 2142104; accession 0001213900-26-113816.

Kat Ipo 2026 10 30

105KB ∙ PDF file

Download

Download

Substantive updates to included coverage

Lycia: the final $18 price and 17.64 million base shares supersede its earlier 14.7 million-share, $16-$18 indicative offering. October 27 Form 4 footnotes identify IPO closing on October 26. October 30 ownership reports disclose a Venrock group shared beneficial position of 6,850,237 shares (11.9% on the filing’s 57,680,559-share denominator). The position reconciles to 4,779,793 prior conversion shares, 1,944,444 purchased in the IPO and 126,000 other purchases. Shared ownership across reporting persons is counted once; the denominator alone is not confirmation of underwriter option exercise. These are ownership disclosures, not a revised IPO price.

Sources: October 27 Form 4; October 30 Form 4; October 30 Schedule 13G.

Appreciate you taking the time to read Weekly Snacks. I hope you have found at least some of these links to be interesting enough to dive into yourself.

If you haven’t already, consider hitting the subscribe button below and sharing this Substack with someone you know.

Share

Subscribe now

Leave a comment

Until next week,

Paul Cerro

Weekly Snacks Twitter: @weeklysnacks

Personal Twitter: @paulcerro

Any feedback? Hit reply

Disclaimer: All information provided herein by Weekly Snacks, LLC (“Weekly Snacks”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security.

Please enjoy this week’s flags for recently filed IPO prospectuses. Remember, this Substack is only meant to provide quick text summaries, with a deeper 3-page overview if you’d like to know more.

None of our content is meant to be taken as investment advice or validity of the proposed company/IPO.

Enjoy.

This Week’s IPOs

Lycia Therapeutics, Inc. | LYCA

Lycia develops LYTAC-based medicines that degrade extracellular disease-related proteins, with clinical programs targeting IgE-mediated allergies and Graves’ disease. For the six months ended June 30, 2026, it reported no collaboration revenue and a $19.2 million net loss, with $148.1 million in cash, cash equivalents and marketable securities at period-end. The final prospectus offers 17.64 million primary shares at $18.00, producing $317.52 million in gross proceeds and approximately $290.7 million in estimated net proceeds. The underwriters have an option for 2.646 million additional shares. Expected October 26 delivery is not confirmation of closing. The base share count matches the additional registration reported on October 22. The development programs remain exposed to clinical, regulatory and manufacturing uncertainty; differentiated scientific approaches require further validation. What to monitor: Final transaction disclosures and subsequent financing, clinical enrollment and data releases, operating cash use, and any changes to the disclosed development timelines. Historical liquidity is a period-end balance and does not represent current cash or a forecast of runway.

Source: 424B4 filed 2026-10-23.

Lycia Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Rezera Inc. | RZRA

Rezera develops oral NLRP3 inhibitors, with ruvonoflast being advanced toward a Phase 3 peripheral artery disease trial and trabzanoflast in neurological development. For the six months ended June 30, 2026, it reported no revenue, a $25.5 million net loss and $3.9 million in cash and cash equivalents at period-end. July financing included $15.2 million in gross preferred-stock proceeds and a $15 million term-loan draw. Those transactions postdate the June cash balance. Substantial doubt about the company’s ability to continue as a going concern remained after the financing. Offer price, share count and estimated proceeds are not disclosed in this filing. The development programs remain exposed to clinical, regulatory and manufacturing uncertainty; differentiated scientific approaches require further validation. What to monitor: Final transaction disclosures and subsequent financing, clinical enrollment and data releases, operating cash use, and any changes to the disclosed development timelines. Historical liquidity is a period-end balance and does not represent current cash or a forecast of runway.

Source: S-1 filed 2026-10-21.

Rezera Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Aspen Neuroscience, Inc. | ASPE

Aspen develops autologous cell therapies, led by sasineprocel for Parkinson’s disease, with a preclinical microglia program for pediatric leukodystrophies. For the six months ended June 30, 2026, it reported no revenue, a $36.5 million net loss and $72.4 million in cash, cash equivalents and marketable securities at period-end. The filing discloses substantial doubt about the company’s ability to continue as a going concern. Sasineprocel is in an early-stage, open-label study; clinical observations do not establish efficacy against a randomized comparator. Offer price, share count and net proceeds are not disclosed. The amendment expands manufacturing-patent risk disclosures and revises capitalization treatment for forgiven officer and director notes. The development programs remain exposed to clinical, regulatory and manufacturing uncertainty; differentiated scientific approaches require further validation. What to monitor: Final transaction disclosures and subsequent financing, clinical enrollment and data releases, operating cash use, and any changes to the disclosed development timelines. Historical liquidity is a period-end balance and does not represent current cash or a forecast of runway.

Source: S-1/A filed 2026-10-22.

Aspen Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Georgia Banking Company | GBC / Nasdaq Capital Market

Georgia Banking operates an Atlanta-area commercial banking franchise. Its October 20 S-1/A registers 7,074,016 shares in a direct-listing transaction; this is resale coverage, not a primary capital raise. For the six months ended June 30, 2026, net interest income increased to $55.9 million from $46.9 million, net interest margin rose to 4.36% from 4.17%, and net income increased to $13.3 million from $6.7 million. June assets were approximately $3.3 billion and deposits $2.8 billion. Results include acquisitions: Georgia Primary was acquired in March 2025 and Tandem in June 2026, limiting organic-growth comparisons. Commercial real estate concentration, large loan relationships, deposit liquidity and integration costs are material considerations. The June private placement and subordinated-note transactions are separate from the direct listing.

What to monitor: Final transaction terms, the next reported financial period, and measurable changes to the operating or development milestones described above.

SEC prospectus. Figures are historical unless explicitly described as proposed; offering completion is not asserted.

Georgia Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Neo Aeronautics | NEOA / proposed NYSE American

Neo develops vertical-takeoff-and-landing aircraft for recreational, logistics and customized applications. Its October 22 S-1/A proposes 3.75 million primary and 1.25 million secondary shares at $4-$6. Secondary proceeds belong to sellers. The company has not generated product revenue. For the first half of 2026 it recorded a S$408,916 net loss, S$470,135 operating cash outflow and S$190,508 ending cash. The financial statements disclose substantial going-concern doubt. Founder Neo Kok Beng holds all Class B shares, each carrying 15 votes, giving approximately 69.12% post-offering voting power including his Class A holding. Product development, regulatory qualification and commercialization remain prospective. The filing contains inconsistent conversion, proceeds and share figures across sections; those discrepancies must remain explicit rather than be silently harmonized.

What to monitor: Final transaction terms, the next reported financial period, and measurable changes to the operating or development milestones described above.

SEC prospectus. Figures are historical unless explicitly described as proposed; offering completion is not asserted.

Neo Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Windward Bio | WWB / proposed Nasdaq Global Market

Windward is a Swiss clinical-stage biotechnology company developing long-acting antibodies for respiratory and dermatologic diseases. WIN378 targets TSLP and is in the POLARIS asthma program and SIRIUS COPD study; WIN027 targets TSLP and IL-13. Management attributes potential dosing convenience to extended half-life, but those claims do not establish comparative efficacy. The October 23 F-1 leaves price, share count and proceeds blank. The IFRS interim statements report a $42.636 million first-half 2026 net loss, $25.886 million operating cash outflow and $207.299 million in cash, equivalents and marketable securities. Property and equipment purchases were $121,000; license-asset payments are separate investing outflows. Licensing dependencies, clinical risk and funding requirements are central considerations. PRC clinical and licensing relationships require completion of the standing geographic screen before publication.

What to monitor: Final transaction terms, the next reported financial period, and measurable changes to the operating or development milestones described above.

SEC prospectus. Figures are historical unless explicitly described as proposed; offering completion is not asserted.

Windward Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Hometown Financial | HFG / proposed Nasdaq Capital Market

Hometown is pursuing a mutual-to-stock conversion connected with TruNorth Bank and a proposed Primary Bank acquisition. The October 23 S-1/A specifies a $10 subscription price and at least 51 million shares sold to complete the conversion. The employee-plan participation-interest supplement is not a separate additional capital raise and must not be counted twice. At September 30, 2026, historical assets were $6.808 billion, deposits $5.676 billion and equity $755.849 million. Quarterly net income was $16.103 million versus $17.128 million a year earlier, despite net interest income rising to $61.807 million from $54.352 million. Loan credit-loss expense increased to $10 million from $1.75 million. Conversion capital, charitable-foundation shares, employee ownership and acquisition effects must be distinguished from historical operating results. Credit quality, capital deployment and compensation costs are key transaction considerations.

What to monitor: Final transaction terms, the next reported financial period, and measurable changes to the operating or development milestones described above.

SEC prospectus. Figures are historical unless explicitly described as proposed; offering completion is not asserted.

Hometown Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

MFB Bancorp | MFDB / intended OTCQB

MFB is a new holding company for Mutual Federal Bank. Its October 23 amendment covers a second-step mutual conversion and replacement of existing Mutual Federal Bancorp shares, which already trade on OTCID as MFDB. It is not a conventional first public listing. The offering covers 765,000 to 1,035,000 shares, potentially increased to 1,190,250, with up to 325,610 exchange shares separately disclosed. September 30 historical assets were $96.161 million, deposits $61.847 million, FHLB advances $16.5 million and equity $16.341 million. Nine-month net income fell to $42,000 from $377,000; net interest income was $2.651 million versus $2.617 million, while noninterest expense rose to $2.643 million from $2.282 million. Capital raised, exchange shares and new benefit-plan dilution require distinct treatment. Profitability, funding costs and capital deployment are central considerations.

What to monitor: Final transaction terms, the next reported financial period, and measurable changes to the operating or development milestones described above.

SEC prospectus. Figures are historical unless explicitly described as proposed; offering completion is not asserted.

Mfb Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

OPay | OPAY / proposed NYSE

OPay provides payments and lending services primarily in emerging markets. The October 23 F-1/A proposes 16 million ADSs at $19-$21, each representing ten ordinary shares, plus an option for 2.4 million ADSs. A separate conditional Standard Bank placement must not be counted as IPO proceeds. First-half 2026 revenue was $467.060 million versus $197.477 million, a calculated increase of 136.5%; Nigeria accounted for 89.5% of revenue. Operating income was $131.237 million versus $35.798 million. Expected-credit-loss provision increased to $118.355 million from $38.137 million, illustrating the lending component of growth. The Indonesian VIE is not direct equity ownership. Currency exposure, credit losses, customer-funds treatment and regulatory requirements warrant separate analysis. Singapore headquarters alone does not resolve the outstanding geographic/control screen.

What to monitor: Final transaction terms, the next reported financial period, and measurable changes to the operating or development milestones described above.

SEC prospectus. Figures are historical unless explicitly described as proposed; offering completion is not asserted.

Opay Weekly Snacks Ipo Brief

103KB ∙ PDF file

Download

Download

Appreciate you taking the time to read Weekly Snacks. I hope you have found at least some of these links to be interesting enough to dive into yourself.

If you haven’t already, consider hitting the subscribe button below and sharing this Substack with someone you know.

Share

Subscribe now

Leave a comment

Until next week,

Paul Cerro

Weekly Snacks Twitter: @weeklysnacks

Personal Twitter: @paulcerro

Any feedback? Hit reply

Disclaimer: All information provided herein by Weekly Snacks, LLC (“Weekly Snacks”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security.

Please enjoy this week’s flags for recently filed IPO prospectuses. Remember, this Substack is only meant to provide quick text summaries, with a deeper 3-page overview if you’d like to know more.

None of our content is meant to be taken as investment advice or validity of the proposed company/IPO.

Enjoy.

This Week’s IPOs

VME Companies, Inc.

VME Companies, Inc. (proposed Nasdaq Capital Market: VME) filed its latest S-1/A on October 13, 2026. The Texas holding company supplies process equipment, separation packages and modular engineering, procurement and construction services for energy projects. It proposes 4 million primary shares at $4-$5, implying $16-$20 million gross proceeds before the over-allotment option. Net proceeds and dollar allocations remain undisclosed; planned uses include project working capital, engineering capacity, balance-sheet support and general purposes.

Historical combined revenue fell from $188.8 million in 2024 to $52.1 million in 2025; H1 2026 revenue declined 38.0% to $25.0 million. H1 gross margin recovered to 25.0%, but net loss was $0.59 million. Operating cash flow of $0.45 million fell short of $0.95 million in PPE purchases. Specialized engineering experience and customer relationships are business strengths; project cyclicality, working-capital requirements, going-concern uncertainty and concentrated legacy ownership are material concerns.

What to monitor: Final proceeds, backlog conversion and contract-margin consistency. The summary cash figures differ from the financial statements, so this takeaway remains provisional pending reconciliation.

Source: S-1/A; accession 0001575872-26-000691.

Vme Companies Ipo

103KB ∙ PDF file

Download

Download

KiNRG, Inc.

KiNRG, Inc. (proposed NYSE American: BYOP) filed its latest S-1/A on October 13, 2026. It combines acquired TRINITY construction and construction-management operations with development-stage hybrid tower renewable power technology. The offer comprises 3 million primary shares at $5-$7, with approximately $16.1 million estimated net proceeds at the $6 midpoint. Planned uses include $5.5 million for structural design, $3.5 million for engineering and integration, $2.5 million for site selection, and the remainder for working capital and general purposes.

H1 2026 historical issuer revenue was $369.2 million and net income $15.9 million, reflecting acquisition timing rather than organic comparability with the pre-acquisition issuer. Operating cash flow was $107.7 million, heavily influenced by increases in construction payables and retentions. TRINITY’s execution history and reported backlog provide an operating base, while HTR construction has not begun and modeled performance remains unvalidated. Project financing, related-party transactions, working capital and going-concern disclosures warrant emphasis.

What to monitor: Acquisition-adjusted comparability, HTR development and final capitalization. Summary and detailed pro forma earnings differ; this takeaway remains provisional and does not use those conflicting earnings for valuation.

Source: S-1/A; accession 0001213900-26-109090.

Kinrg Ipo

103KB ∙ PDF file

Download

Download

Cashlin

Cashlin (ticker and exchange not disclosed) filed its initial S-1 on October 15, 2026. It provides inventory-reorder and cash-planning SaaS for direct-to-consumer supplement-subscription brands. The self-underwritten, best-efforts offer registers 10 million primary shares at a fixed $0.10, with no minimum or escrow. Maximum gross proceeds are $1 million and estimated net proceeds $985,000, allocated to development, marketing, a $3,000 founder-facility repayment, and working capital.

Commercial operations began June 15. Three twelve-month, non-renewing contracts represent $30,000 annual fees; this is not renewal-backed ARR. From June 1 inception through June 30, revenue was $1,315, net income $711 and operating cash flow $2,281. Cash was $3,181; the balance sheet includes a founder software-acquisition note with $70,000 face value. A focused workflow and initial customer receipts provide a starting platform, while customer concentration, future amortization, insider transactions and uncertain OTCQB quotation remain concerns. The financial statements are labeled unaudited despite audited wording elsewhere in the filing.

What to monitor: Customer replacement after June 2027, cash costs, funds raised and quotation status. A full sale would leave founders with 60% ownership.

Source: S-1; accession 0001683168-26-007889.

Cashlin Ipo

103KB ∙ PDF file

Download

Download

NuvOx Therapeutics, Inc.

NuvOx Therapeutics, Inc. (proposed NYSE American: NUOX) filed its latest S-1/A on October 13, 2026. The clinical-stage company develops NanO2, an intravenous oxygen-delivery therapy for hypoxic tissue, with programs in glioblastoma, ischemic stroke and respiratory distress. It proposes 2.86 million primary shares at $6-$8; estimated net proceeds are $17.4 million at the $7 midpoint. Funding is designated for clinical trials, Phase III preparation and working capital, rather than a secondary shareholder sale.

H1 2026 revenue was $0.567 million, predominantly grants, versus $0.592 million a year earlier. Operating loss widened to $2.894 million; the $6.006 million net loss includes substantial financing-related fair-value movements and a debt-amendment gain. Operating cash outflow was $1.268 million, with $0.332 million cash at June 30. Early human data, issued patents and multiple clinical programs provide a development foundation; uncertain efficacy, reported safety events, going-concern uncertainty and conversion-related dilution remain significant risks. Company clinical and competitive claims are not independently validated here.

What to monitor: Trial enrollment and results, safety attribution, financing completion and the conversion-adjusted share count. Final pricing and exchange approval remain pending.

Source: S-1/A; accession 0001213900-26-108590.

Nuvox Therapeutics Ipo

103KB ∙ PDF file

Download

Download

Appreciate you taking the time to read Weekly Snacks. I hope you have found at least some of these links to be interesting enough to dive into yourself.

If you haven’t already, consider hitting the subscribe button below and sharing this Substack with someone you know.

Share

Subscribe now

Leave a comment

Until next week,

Paul Cerro

Weekly Snacks Twitter: @weeklysnacks

Personal Twitter: @paulcerro

Any feedback? Hit reply

Disclaimer: All information provided herein by Weekly Snacks, LLC (“Weekly Snacks”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security.

It’s been a minute! Weekly Snacks was originally founded over three years ago as one of the first aggregators for investment pitches, general research, and interesting Tweets. To be frank, keeping up with it got tedious for me, especially while I was out building Cedar Grove Capital Management.

However, I still own Weekly Snacks, the domain, and its socials, and still wanted something to do with it that didn’t seem like a “job” to me.

In my own process for my fund, I do enjoy researching IPOs. I tend to find a lot of ‘short alpha’ there, which is why my performance with them has been so good (below).

But the above are based on my full-blown notes on IPOs that I think are interesting enough to write about, not every IPO. I still sift through a lot of IPOs to see what might pique my interest and then decide if I want to write a full post on it afterwards. As I’m sure you know, there’s a lot of content out there to sift through, and there are only 24 hours in a day.

How can we decide what’s worth looking at?

Well, I have my own process, but when I got to thinking about it more, I felt that maybe it would be good enough to share via Weekly Snacks. This is why I’m relaunching Weekly Snacks as a quick IPO monitor that highlights a quick summary of the IPO (via AI), and if you want to dive deeper, you can download the AI-generated PDF. Sent out weekly, if there’s something to send out.

That’s it. Simple and to the point. It’s nothing that I don’t already do on my end for idea generation, and I’m just extending it to you all via this.

So please, take a look at our first iteration, and let me know your thoughts, comments, feedback, etc.

At the end of the post, you’ll find a quick survey (2 questions) on whether you like this or not. Your feedback would be greatly appreciated so I can make this better!

Also, this is completely free! Just enjoy it, and please make sure to like/subscribe if you think it’s helpful to your process.

This Week’s IPOs

Centinel Spine | Proposed NYSE: CNTL

Filing: S-1, October 7, 2026. Pricing: Not disclosed.

Centinel Spine sells prodisc artificial spinal discs, a motion-preserving alternative to fusion for eligible patients. Revenue increased 39% to $132.2 million in 2025 and 42% to $85.2 million in H1 2026. H1 gross margin was 82.2%, adjusted EBITDA was $15.5 million, and GAAP net income was $10.2 million.

The primary equity offering will fund debt repayment, offering costs, commercial expansion, R&D, instruments/inventory and working capital. Some repayments benefit related-party lenders. The initial S-1 does not disclose the price range, shares offered, proceeds or valuation.

Potential competitive advantages include an established clinical platform, regulatory approvals and expanding surgeon adoption. Disclosed risks include reimbursement, larger competitors, single-source suppliers and an Up-C structure with a tax receivable agreement allocating 85% of certain tax benefits to existing owners. H1 net income included a $3.8 million warrant/derivative gain, while 2025 free cash flow was negative.

What to monitor: Final pricing, the fully diluted economic share count, post-IPO debt, proceeds allocation, and the tax receivable agreement’s effect on future cash flows.

Source: SEC S-1

Weekly Snacks Centinel Ipo Overview

106KB ∙ PDF file

Download

Download

Georgia Banking Company | Proposed Nasdaq: GBC

Filing: S-1, October 2, 2026. Structure: Direct listing/resale, rather than a capital-raising IPO.

Georgia Banking Company, Inc. operates an Atlanta-focused bank serving commercial, real estate, private banking, mortgage warehouse and treasury clients. At June 2026, it had $3.26bn of assets, $2.84bn of deposits and 10 branches. Acquisitions of Georgia Primary in 2025 and Tandem in June 2026 expanded its franchise and affect financial comparisons.

The S-1 registers up to 7,040,514 existing shares. Selling shareholders receive sale proceeds; the company receives none and bears listing expenses. The opening public price is not disclosed. The filing’s $30 private-transaction price is historical context, not a public pricing estimate.

H1 2026 net interest income rose 19.3% to $55.9m and GAAP net income rose 97.5% to $13.3m. Net interest margin improved to 4.36%; adjusted net income, excluding after-tax merger expenses, was $15.9m. Improved earnings and a larger local network are business strengths. Credit and funding sensitivities include commercial real estate at 58.8% of investment loans, uninsured deposits at 44.1% and geographic concentration. The listing has no contractual shareholder lock-ups.

What to monitor: Opening-market price, organic growth versus acquired balances, deposit retention, credit quality and regulatory capital.

Source: SEC S-1.

Weekly Snacks Georgia Banking Ipo Overview

105KB ∙ PDF file

Download

Download

TFP Group Limited | Proposed NYSE: TFP

Filing: F-1, September 25, 2026. Pricing: Not disclosed.

TFP Group Limited, known as The Fidelis Partnership, is a specialty insurance managing general agent. Fidelis Underwriting and Pine Walk originate risks on third-party insurance capacity; TFP earns placement and profit commissions rather than operating as an insurance carrier. Placement commissions represented 90% of H1 2026 revenue.

The proposed offering combines company-issued ordinary shares and selling-shareholder shares. Price range, share counts and net proceeds remain blank. Company proceeds and existing cash will repay part of the new term loan, with any remainder for general corporate purposes; secondary proceeds go to selling holders. The August refinancing established a $2.04bn term loan before IPO repayment.

H1 revenue increased 11.4% to $407.5m, while company-adjusted EBITDA rose 4.1% to $244.8m and its margin declined to 60.1%. GAAP net income was $127.5m, including $39.0m of equity-investment gains. Scale, specialized underwriting and long-term capacity relationships are strengths; 70% of LTM bound premium had long-term capacity support. Constraints include leverage, premium-cycle exposure and concentration: Pelagos supported 48% of LTM bound premium, net of reinsurance. A fiduciary-balance control weakness caused a balance-sheet restatement, without a stated earnings or cash-flow effect.

What to monitor: Offer valuation, debt repayment, ownership/float, commission margins, capacity mix and control remediation.

Source: SEC F-1.

Weekly Snacks Tfp Group Ipo Overview

105KB ∙ PDF file

Download

Download

TRex Bio | Nasdaq: TRXB

Filing: Final 424B4, October 9, 2026. Pricing: $14 per share, final prospectus.

TRex Bio, Inc. develops therapies that activate tissue regulatory T cells to address autoimmune and inflammatory disease. Its lead wholly owned candidate, TRB-061, is in a Phase 1a/b trial involving healthy volunteers and patients with moderate-to-severe atopic dermatitis. Phase 1b patient topline data are expected in mid-2027; TRB-071 is in IND-enabling development.

The final prospectus offers 8,333,334 primary shares at $14, producing approximately $116.7m gross and $103.5m estimated net proceeds. No secondary shares are included. Net proceeds plus existing liquidity fund approximately $90m for TRB-061, $10m for TRB-071 and remaining working capital/general purposes. Management projects funding into H2 2029 under its current operating plan.

H1 2026 revenue was zero, net loss was $29.3m and operating cash use was $27.0m. June cash and securities totaled $90.9m before the IPO. The tissue-Treg platform, defined pipeline and Lilly licensing relationship are strengths, but no approved products or product sales exist. Patient efficacy remains unproven; rising development costs, equity dilution and a technical-accounting control weakness are material risks.

What to monitor: TRB-061 patient data, TRB-071 clinical entry, spending against the stated plan and reporting-control remediation.

Source: SEC final prospectus.

Weekly Snacks Trex Bio Ipo Overview

105KB ∙ PDF file

Download

Download

Santa Ana Global Enterprises | Proposed NYSE American: STNF

Filing: F-1, September 18, 2026. Pricing: Indicative $13-15 per ADS; not final.

Santa Ana Global Enterprises, S.A. is a Spanish holding company pursuing planned-community projects in Chile, Colombia, Panama and Costa Rica. Its ordinary shares already trade on BME Growth as STNA. The proposed U.S. offering comprises 1,154,000 ADSs, each representing one ordinary share.

At the $14 midpoint, gross proceeds would be $16.16m and estimated net proceeds $13.53m. The latter includes deductions for already-paid and noncash costs and is not closing-date cash. Proceeds repay $1.5m of Yorkville principal plus an assumed premium; remaining funds support selected land/project payments, pre-development and working capital.

Latest audited FY2025 results show no revenue, a EUR3.02m net loss and EUR1.97m operating cash use. Year-end cash was EUR53,752. The 2024 inception-period profit largely reflected a noncash land-valuation gain, limiting comparability. A five-project, four-country pipeline and management’s development experience provide organizational strengths, but rights remain conditional and no pre-sales have commenced. Going-concern uncertainty, uncommitted construction financing and undocumented oral deferral of overdue Panama payments are significant risks. Company-estimated lifetime project investment is $1.075bn, far beyond proposed IPO funding.

What to monitor: Updated liquidity, definitive land/trust documents, payment arrangements, permits, binding financing, pre-sales and final dilution.

Source: SEC F-1.

Weekly Snacks Santa Ana Ipo Overview

105KB ∙ PDF file

Download

Download

Appreciate you taking the time to read Weekly Snacks. I hope you have found at least some of these links to be interesting enough to dive into yourself.

If you haven’t already, consider hitting the subscribe button below and sharing this Substack with someone you know.

Share

Subscribe now

Leave a comment

Until next week,

Paul Cerro

Weekly Snacks Twitter: @weeklysnacks

Personal Twitter: @paulcerro

Any feedback? Hit reply

Disclaimer: All information provided herein by Weekly Snacks, LLC (“Weekly Snacks”) is for informational purposes only and does not constitute investment advice or an offer or solicitation to buy or sell an interest in a private fund or any other security.